Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
Get Alerts BNTC Hot Sheet
Join SI Premium – FREE
HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024.
Date: November 11, 2024
Time: 2:30 PM
Format: Fireside Chat & 1x1 Meetings
The Benitec presentation will also be available via live webcast here.
Please contact your Guggenheim representative to schedule a 1x1 meeting with Benitec management.
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.
Investor Relations Contact:
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
[email protected]
Source: Benitec Biopharma Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CZR Token Completes CertiK Smart-Contract Audit Ahead of October 1 Launch
- Syracuse Estate Planning Attorney Frederick P. Davies Details the Living Trust Administration Process in New York
- Reuters Momentum AI Austin Day 1: A New Way to Measure Whether AI Is Actually Paying Off
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share